July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
High-dimensional immune cell profiling characterizes features of peripheral NK cell repertoires in CMV anterior uveitis
Author Affiliations & Notes
  • Nobuyo Yawata
    Fukuoka Dental College, Fukuoka, FUKUOKA, Japan
    Kyushu University, Japan
  • Jay Siak
    Singapore Eye Research Institute, Singapore
    Singapore National Eye Centre, Singapore
  • Kaing Woon
    Singapore Eye Research Institute, Singapore
  • Xinru Lim
    Singapore Eye Research Institute, Singapore
  • Soon Phaik Chee
    Singapore Eye Research Institute, Singapore
    Singapore National Eye Centre, Singapore
  • Makoto Yawata
    National University of Singapore, Singapore
  • Yoichi Kawano
    Fukuoka Dental College, Fukuoka, FUKUOKA, Japan
  • Koh-hei Sonoda
    Kyushu University, Japan
  • Footnotes
    Commercial Relationships   Nobuyo Yawata, None; Jay Siak, None; Kaing Woon, None; Xinru Lim, None; Soon Phaik Chee, None; Makoto Yawata, None; Yoichi Kawano, None; Koh-hei Sonoda, None
  • Footnotes
    Support  NMRC/TA/010/2012, MEXT KAKENHI JP18K090467, NMRC/CNIG 1113/2013, SNEC HREF R1043/58/2013
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 821. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nobuyo Yawata, Jay Siak, Kaing Woon, Xinru Lim, Soon Phaik Chee, Makoto Yawata, Yoichi Kawano, Koh-hei Sonoda; High-dimensional immune cell profiling characterizes features of peripheral NK cell repertoires in CMV anterior uveitis. Invest. Ophthalmol. Vis. Sci. 2019;60(9):821.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In CMV anterior uveitis (CMV-AU), recurrent intraocular inflammation is triggered by CMV reactivation in individuals in the absence of apparent systemic immunodeficiency. NK cells are innate lymphocytes regulating CMV infection, and NKG2C has been considered an NK cell receptor that is utilized to recognize CMV infection in human. CMV infection is known to induce immunosenescence and leave an imprint on the NK cell receptor repertoire. NKG2C+CD57+NK cells expand in CMV seropositive human individuals, whereas Ly49H+KLRG1+NK cells expand in rodents where NKG2C and CD57 are absent. To assess NK cell profiles in CMV-AU, we compared the peripheral NK cell profiles in CMV-AU against those in CMV seropositive healthy individuals with maturation markers used in human (CD57) and rodents (KLRG1).

Methods : Peripheral blood mononuclear cells were isolated from 15 CMV-AU patients, 15 age-matched CMV seropositive healthy individuals, and 3 CMV seronegative individuals. We analyzed the NK cell profiles of receptors thought to be involved in CMV recognition in association with NK cell maturation markers: KLRG1, CD57, Killer cell Immunoglobulin-like receptors (KIRs), NKG2C, and NKG2A using high-dimensional flow cytometry. A CMV-pp65 random peptide library was tested for the capacity to induce proinflammatory cytokine responses in NK cells.

Results : We identified four distinct NK subsets determined by KLRG1 and CD57 expression regardless of CMV serostatus. Expression profiles of KIRs and NKG2A in each subset implies that the CD57+KLRG1- subset is most differentiated followed by the CD57+KLRG1+ subset. These two subsets were the most dominant in CMV-AU and CMV seropositive healthy controls. NKG2C expression frequencies were diverse (2-82%) and the distribution pattern was different between CMV-AU and CMV seropositive controls. Notably, significant increase of IFN-g production was observed in the CD57+KLRG1+NKG2C- NK cells upon CMV-pp65 stimulation. Expression cluster analysis identified NK subsets unique to CMV-AU, which could be responsive to CMV-pp65.

Conclusions : These results infer that human NK cells utilize receptors other than NKG2C for CMV recognition and differences in anti-CMV immunity mediated by peripheral NK cells are involved in the development of CMV-AU.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×